Novartis Stock Screener | Share Price & Fundamental Analysis
NOVARTIND
Pharmaceuticals
Screen Novartis share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹784.55
▲
5.15 (0.66%)
Market Cap
₹1,924.40 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.48
EPS (TTM)
₹40.87
Dividend Yield
3.21%
Debt to Equity
0.01
52W High
₹1081.55
52W Low
₹746.15
Operating Margin
28.00%
Profit Margin
27.02%
Revenue (TTM)
₹396.00
EBITDA
₹142.00
Net Income
₹107.00
Total Assets
₹948.00
Total Equity
₹785.00
Novartis Share Price History - Stock Screener Chart
Screen NOVARTIND historical share price movements with interactive charts. Analyze price trends and patterns.
Novartis Company Profile - Fundamental Screener
Screen Novartis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NOVARTIND shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE234A01025
Novartis Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen NOVARTIND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 948 | 925 | 983 | 958 | 1,002 | 1,078 | 982 | 1,111 | 1,150 | 1,433 |
| Current Assets | 746 | 699 | 677 | 709 | 723 | 813 | 807 | 952 | 973 | 1,264 |
| Fixed Assets | 5 | 7 | 19 | 24 | 64 | 76 | 15 | 5 | 6 | 7 |
| Liabilities | ||||||||||
| Total Liabilities | 948 | 925 | 983 | 958 | 1,002 | 1,078 | 982 | 1,111 | 1,150 | 1,433 |
| Current Liabilities | 21 | 23 | 48 | 50 | 132 | 124 | 38 | 47 | 47 | 35 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 785 | 745 | 776 | 692 | 711 | 721 | 759 | 734 | 920 | 1,194 |
| Share Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 | 16 |
| Reserves & Surplus | 773 | 733 | 763 | 679 | 699 | 708 | 747 | 721 | 906 | 1,178 |
Screen NOVARTIND income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 396 | 398 | 397 | 437 | 433 | 414 | 474 | 569 | 736 | 727 | 771 | 981 |
| Expenses | 254 | 265 | 270 | 314 | 373 | 355 | 426 | 478 | 570 | 631 | 656 | 877 |
| EBITDA | 142 | 133 | 127 | 123 | 60 | 60 | 48 | 91 | 166 | 96 | 115 | 104 |
| Operating Profit % | 28.00% | 26.00% | 19.00% | 17.00% | 7.00% | 7.00% | 3.00% | 3.00% | -1.00% | 4.00% | 5.00% | 0.00% |
| Depreciation | 2 | 2 | 3 | 6 | 10 | 12 | 13 | 3 | 3 | 4 | 4 | 4 |
| Interest | 1 | 1 | 2 | 2 | 5 | 8 | 6 | 2 | 6 | 1 | 0 | 0 |
| Profit Before Tax | 139 | 130 | 123 | 115 | -4 | 40 | 29 | 86 | 158 | 92 | 111 | 93 |
| Tax | 32 | 30 | 38 | 12 | 0 | 19 | 19 | 34 | 79 | 35 | 39 | 14 |
| Net Profit | 107 | 101 | 85 | 103 | -4 | 21 | 10 | 52 | 78 | 57 | 73 | 79 |
| EPS | 43.20 | 40.87 | 34.50 | 41.86 | -1.51 | 8.46 | 4.08 | 20.97 | 28.43 | 19.10 | 62.04 | 24.75 |
Novartis Cash Flow Screener - Liquidity Fundamentals
Screen NOVARTIND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 75 | 113 | 45 | 39 | -69 | -23 | -194 | 161 | -41 | 57 |
| Investing Activities | -3 | 33 | -153 | 87 | 95 | 56 | 274 | 69 | 424 | -631 |
| Financing Activities | -64 | -121 | -31 | -36 | -37 | -41 | -30 | -268 | -332 | -39 |
| Net Cash Flow | 7 | 26 | -139 | 90 | -11 | -9 | 50 | -38 | 51 | -613 |
Screen NOVARTIND shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FII Holding | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.00% |
| DII Holding | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.78% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.11% | 22.95% | 22.92% | 22.95% | 23.04% | 23.05% | 23.01% | 23.03% |
| Other Holding | 5.49% | 5.66% | 5.68% | 5.65% | 5.57% | 5.55% | 5.59% | 5.51% |
| Shareholder Count | 39,133 | 39,040 | 39,353 | 41,239 | 39,265 | 39,596 | 38,926 | 41,947 |
Novartis Dividend Screener - Share Yield Analysis
Screen NOVARTIND dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹25.00 | 3.21% |
| 2024-March | ₹25.00 | 3.18% |
| 2023-March | ₹47.50 | 4.62% |
| 2022-March | ₹10.00 | 1.76% |
| 2021-March | ₹10.00 | 1.69% |
| 2020-March | ₹10.00 | 1.81% |
| 2019-March | ₹10.00 | 1.99% |
| 2018-March | ₹10.00 | 1.46% |
| 2017-March | ₹10.00 | 1.63% |
Novartis Index Membership - Market Screener Classification
Screen NOVARTIND by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Novartis Market Events Screener - Corporate Actions
Screen NOVARTIND market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | 0.39% |
| 2025-10-28 | 2025-10-28 | Quarterly Result Announcement | NA | -3.77% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 24.87% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -0.92% |
| 2025-07-23 | 2025-07-23 | Dividend | ₹ 25.00 /share | 33.11% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | -3.94% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -4.09% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -9.21% |
| 2024-07-31 | 2024-07-31 | Annual General Meeting | NA | 11.66% |
| 2024-07-23 | 2024-07-24 | Dividend | ₹ 25.00 /share | 5.99% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 37.50 /share | 32.63% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 10.00 /share | 32.63% |
| 2022-07-20 | 2022-07-22 | Dividend | ₹ 10.00 /share | 7.03% |
| 2021-08-17 | 2021-08-20 | Dividend | ₹ 10.00 /share | -11.14% |
Novartis Competitors Screener - Peer Comparison
Screen NOVARTIND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 414,605 | 39.37 | 54,729 | 9.71% | 10,980 | 42.10 |
| Divis Laboratories | 169,701 | 67.76 | 9,712 | 18.67% | 2,191 | 48.20 |
| Torrent Pharmaceuticals | 131,496 | 60.85 | 11,539 | 6.99% | 1,911 | 67.66 |
| Cipla | 122,103 | 22.30 | 28,410 | 7.12% | 5,291 | 51.10 |
| Dr Reddys Laboratories | 104,838 | 18.24 | 33,741 | 16.73% | 5,725 | 45.31 |
| Lupin | 96,170 | 22.10 | 22,910 | 13.74% | 3,306 | 56.06 |
| Zydus Life Science | 92,262 | 18.30 | 23,511 | 18.55% | 4,615 | 45.37 |
| Mankind Pharma | 90,929 | 50.34 | 12,744 | 20.90% | 2,007 | 50.55 |
| Aurobindo Pharma | 70,591 | 20.25 | 32,346 | 9.43% | 3,484 | 56.45 |
| Alkem Laboratories | 66,867 | 27.11 | 13,458 | 3.70% | 2,216 | 50.91 |
Novartis Company Announcements - News Screener
Screen NOVARTIND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-03 | Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Novartis India Limited To Inter Alia Consider And Approve The Unaudited Financial Results For Quarter Ended December 31 2025. | View |
| 2026-01-03 | Closure of Trading Window | View |
| 2025-11-24 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (The Listing Regulations) | View |
| 2025-11-24 | Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order | View |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-28 | Integrated Unaudited Financial Results And Limited Review Report For The Quarter And Half-Year Ended September 30 2025. | View |
| 2025-10-28 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday October 28 2025 | View |
| 2025-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Board Meeting Intimation for Inter Alia Considering The Unaudited Financial Results For The Half Year And Quarter Ended September 30 2025. | View |
| 2025-09-30 | Closure of Trading Window | View |
| 2025-08-01 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-07-31 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-07-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-07-29 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-07-29 | Unaudited Financial Results For The Quarter Ended As On June 30 2025. | View |
| 2025-07-29 | Board Meeting Outcome for Intimation About The Outcome Of The Board Meeting Held On July 29 2025 Inter Alia For The Approval Of Unaudited Financial Statements For The Quarter Ending As On June 30 2025. | View |
| 2025-07-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-07-11 | Intimation About The 77Th Annual General Meeting ("AGM") And Weblink Of The Annual Report For F.Y 2024-25 Of The Novartis India Limited ("The Company") To The Shareholders By Way Of Physical Dispatch Of Letters | View |
| 2025-07-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-07-04 | Business Responsibility and Sustainability Reporting (BRSR) | View |